Novel NanoLuc-type substrates with various C-6 substitutions
Chongzheng Yan1, Lupei Du1, Minyong Li2
1Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan, Shandong 250012, China.
Bioorganic & Medicinal Chemistry Letters
|March 16, 2020
Summary
Researchers developed new NanoLuc (NLuc) bioluminescent substrates, A6 and A11, offering superior performance over standard furimazine. These enhanced NLuc substrates improve bioluminescence for applications like in vivo imaging.
Area of Science:
- Biochemistry
- Molecular Biology
- Biotechnology
Background:
- The NanoLuc (NLuc)-furimazine bioluminescence system offers advantages like enhanced stability and a smaller size.
- Existing bioluminescence systems have limitations that newer substrates aim to overcome.
- A >150-fold enhancement in bioluminescence is a key feature of the NLuc system.
Purpose of the Study:
- To design and synthesize novel bioluminescent substrates for the NLuc-furimazine system.
- To evaluate the bioluminescence characteristics of new substrates compared to standard furimazine.
- To explore the potential of these new substrates in in vitro and in vivo applications, particularly bioluminescent imaging.
Main Methods:
- Chemical synthesis of a series of furimazine derivatives with modifications at the C-6 position.
- In vitro assessment of bioluminescence characteristics of synthesized compounds.
- In vivo evaluation of the performance of lead compounds in biological systems.
Main Results:
- Compounds A6 and A11 demonstrated significantly improved bioluminescence characteristics compared to the parent furimazine.
- Both in vitro and in vivo studies confirmed the superior performance of A6 and A11.
- The modified substrates maintained or enhanced the inherent advantages of the NLuc system.
Conclusions:
- Novel NLuc substrates, specifically A6 and A11, have been successfully designed and synthesized.
- These new substrates offer enhanced bioluminescence, making them valuable tools for NLuc-based assays.
- The developed NLuc substrates are expected to expand the utility of NLuc bioluminescence techniques, especially for in vivo imaging.
Related Concept Videos
02:34Nucleophilic Substitution Reactions
18.8K
Historical perspective
In 1896, the German chemist Paul Walden discovered that he could interconvert pure enantiomeric (+) and (-) malic acids through a series of reactions. This conversion suggested the involvement of optical inversion during the substitution reaction. Further, in 1930, Sir Christopher Ingold described for the first time two different forms of nucleophilic substitution reactions, which are known as SN1 (nucleophilic substitution unimolecular) and SN2 (nucleophilic substitution...
In 1896, the German chemist Paul Walden discovered that he could interconvert pure enantiomeric (+) and (-) malic acids through a series of reactions. This conversion suggested the involvement of optical inversion during the substitution reaction. Further, in 1930, Sir Christopher Ingold described for the first time two different forms of nucleophilic substitution reactions, which are known as SN1 (nucleophilic substitution unimolecular) and SN2 (nucleophilic substitution...
18.8K
02:30Stability of Substituted Cyclohexanes
14.5K
This lesson discusses the stability of substituted cyclohexanes with a focus on energies of various conformers and the effect of 1,3-diaxial interactions.
The two chair conformations of cyclohexanes undergo rapid interconversion at room temperature. Both forms have identical energies and stabilities, each comprising equal amounts of the equilibrium mixture. Replacing a hydrogen atom with a functional group makes the two conformations energetically non-equivalent.
For example, in...
The two chair conformations of cyclohexanes undergo rapid interconversion at room temperature. Both forms have identical energies and stabilities, each comprising equal amounts of the equilibrium mixture. Replacing a hydrogen atom with a functional group makes the two conformations energetically non-equivalent.
For example, in...
14.5K